Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…
Tianneng joins Swiss listing bandwagon, even as frosty reception awaits
The battery maker could become the 11th Chinese company to list global depositary receipts (GDRs) in Switzerland, heeding Beijing’s call for companies to raise their global profile Key Takeaways: Tianneng…
Riding Covid Vaccine Highs, CanSino Plans Swiss Listing
The first vaccine stock to be listed in the both Mainland China and Hong Kong will issue global depositary receipts (GDRs) in SwitzerlandKey Takeaways:After successful listings in Shanghai and Hong…
Chinese Firms in New GDR Rush to Realize Global Dreams
Six Chinese companies have announced plans to issue global depositary receipts in Europe, following Beijing’s recent show of support for overseas listings Key takeaways: Six domestically listed Chinese companies have…
Recent Articles
RELATED ARTICLES
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG -
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
Missing the Covid boat, Junshi stumbles back to old business
1877.HK 688180.SHG
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
